Harmony Biosciences (HRMY) shares were up 6.2% in early Tuesday trading after the company posted higher Q2 results.

The company reported Q2 earnings of $1.28 per diluted share, up from $0.68 a year earlier.

Analysts polled by FactSet expected $0.96.

Net product revenue for the quarter ended June 30 was $261.3 million, up from $200.5 million a year earlier.

Analysts expected revenue of $250.8 million.

Harmony reiterated its 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

As of June 30, the company said it had $962.5 million in cash, cash equivalents and investments.

Price: 37.81, Change: +2.21, Percent Change: +6.19